P05.04 Phase 2 open-label study of maintenance treatment with ibrutinib following first line methotrexate-based immuno-chemotherapy in elderly patients with primary CNS lymphoma (PCNSL)

MLA

Alexandra Amiel, et al. P05.04 Phase 2 Open-Label Study of Maintenance Treatment with Ibrutinib Following First Line Methotrexate-Based Immuno-Chemotherapy in Elderly Patients with Primary CNS Lymphoma (PCNSL). Sept. 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e95c5fea2548778d6d31b6058536add4&authtype=sso&custid=ns315887.

APA

Alexandra Amiel, Tali Siegal, Ronit Gurion, Osnat Bairey, & Shlomit Yust-Katz. (2019). P05.04 Phase 2 open-label study of maintenance treatment with ibrutinib following first line methotrexate-based immuno-chemotherapy in elderly patients with primary CNS lymphoma (PCNSL).

Chicago

Alexandra Amiel, Tali Siegal, Ronit Gurion, Osnat Bairey, and Shlomit Yust-Katz. 2019. “P05.04 Phase 2 Open-Label Study of Maintenance Treatment with Ibrutinib Following First Line Methotrexate-Based Immuno-Chemotherapy in Elderly Patients with Primary CNS Lymphoma (PCNSL),” September. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e95c5fea2548778d6d31b6058536add4&authtype=sso&custid=ns315887.